WealthCollab’s Corcept Therapeutics CORT Stock Holding History

WealthCollab’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15	Closed	-$522	–	988
2025 Q4	$522	Hold	15	–	–	﹤0.01%	990
2025 Q3	$1.25K	Hold	15	–	–	﹤0.01%	897
2025 Q2	$1.1K	Buy	+15	New	+$1.09K	﹤0.01%	886

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

WealthCollab's CORT Position: Q1 2026 in Review

WealthCollab sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 15 shares — an estimated $522 sold.

WealthCollab first reported a position in CORT in Q2 2025 and held it in 3 quarters. The position peaked at $1.25K in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

WealthCollab reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
WealthCollab sold 15 Corcept Therapeutics shares in Q1 2026, an estimated $522.
WealthCollab first reported a position in Corcept Therapeutics in Q2 2025 and held it in 3 quarters.
WealthCollab's Corcept Therapeutics position peaked at $1.25K in Q3 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on WealthCollab's 13F filing for Q1 2026, filed 13 May 2026.